Clinical trial · Observational
Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.
NCT02090465CI-TRIAL-00042334completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ingenol Mebutate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- all eligible patients
- description
- Treatment with Picato according to Summary of Product Characteristics (SmPC)
- interventionNames
- Drug: Ingenol Mebutate
Primary outcomes (3)
- measure
- Actinic keratosis
- timeFrame
- 8 weeks
- description
- Documentation of the course of actinic keratoses and skin findings during ambulant routine use of Picato®
- measure
- Skindex-16
- timeFrame
- 8 weeks
- description
- Patient' s quality of life during ambulant routine use of Picato®
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: • Non-hyperkeratotic, non-hypertrophic actinic keratoses where treatment with Picato® is indicated and the treatment is intended by physicians. Exclusion Criteria: * Preceding use of Picato® on the area planned for treatment * Any other specific local treatment of actinic keratoses on the area planned for treatment during the last 8 weeks * Melanoma, squamous cell carcinoma or spinalioma on the area planned for treatment * Open wounds on the area planned for treatment * Contraindications according to prescribing information
References
Publications (0)
Data not yet available
No reference posted for this study.